David A. Eichenbaum, MD, FASRS

Clinical Perspectives Comparing Faricimab and Aflibercept 8mg

David Eichenbaum, MD, FASRS concludes this series with the final case of a treatment-experienced patient switching from aflibercept 2 mg to high-dose aflibercept 8 mg with noticeable improvement after the first dose.

Tolerance and Aggression: Achieving Improved Fluid Response

David Eichenbaum, MD, FASRS provides his clinical experience with faricimab and aflibercept 8 mg, highlighting the small and large changes that benefit a patient’s quality of life, such as improved visual anatomy or reducing the frequency of visits.

Case 1: Discussion of Treatment Naïve nAMD With Aflibercept 8mg

David Eichenbaum, MD, FASRS discusses his clinical experience in managing retinal fluid, emphasizing the need to dramatically reduce intraretinal fluid, highlighting different strategies of care that offer the best results for patients.

Take-Home Points for the Treatment of AMD and DME

David Eichenbaum, MD, FASRS discusses a case of exudative macular degeneration and opted for aflibercept 8 mg as treatment, which led to significant improvements in visual acuity and anatomical features.

David A. Eichenbaum, MD, FASRS;Caroline R. Baumal, MD

Unmet Needs in AMD and DME

David A. Eichenbaum, MD, FASRS and Caroline Baumal, MD provide take-home messages to providers treating AMD and DME.

David A. Eichenbaum, MD, FASRS;Caroline R. Baumal, MD

Incorporating Faricimab in Clinical Practice

Drs David A. Eichenbaum and Caroline Baumal discuss unmet needs in treating AMD and DME.

David A. Eichenbaum, MD, FASRS;Caroline R. Baumal, MD

MOA of Faricimab and 2-Year Data Review

Retina specialists discuss how to incorporate faricimab into clinical practice and discuss implacations of the TRUCKEE study.

David A. Eichenbaum, MD, FASRS;Caroline R. Baumal, MD

Implications of Treat-and-Extend With Faricimab in AMD

David A. Eichenbaum, MD, FASRS, and Caroline Baumal, MD, review the dual mechanism of action of faricimab as well as the 2-year update in the TENAYA, LUCERNE, YOSEMITE, and RHINE trials.

David A. Eichenbaum, MD, FASRS;Caroline R. Baumal, MD

AMD and DME: Factors Affecting Treatment Selection and the Importance of Shared Decision-Making

Drs David A. Eichenbaum and Caroline Baumal discuss implications of the treat-and-extend approach with faricimab in patients with wet AMD.

David A. Eichenbaum, MD, FASRS;Caroline R. Baumal, MD

Impact of AMD and DME on Quality of Life

Retina specialists discuss which factors impact treatment selection and how to incorporate shared decision-making into treatment selection when treating patients with AMD and DME.

David A. Eichenbaum, MD, FASRS;Caroline R. Baumal, MD

Impressions and Takeaway Points From nAMD Patient Case #2

David A. Eichenbaum, MD, FASRS, and Caroline Baumal, MD, discuss how AMD and DME impact a patient’s quality of life.

Patient Case #2: 81-Year-Old Male With nAMD

A retina specialist discusses impressions and key takeaway points from the case of an 81-year-old male with treatment-experienced neovascular age-related macular degeneration (nAMD).

Impressions and Takeaway Points From DME Patient Case #1

David A. Eichenbaum, MD, FASRS, reviews the case of a 81-year-old female with treatment experienced neovascular age-related macular degeneration (nAMD).

Patient Case #1: 74-Year-Old Male With DME

A retina specialist discusses impressions and key takeaway points from the case of a 74-year-old man with diabetic macular edema (DME).